跳转至内容
Merck
CN

SML2223

WAY-267464 dihydrochloride

≥98% (HPLC)

别名:

4-(3,5-Dihydroxy-benzyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide dihydrochloride, N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamide dihydrochloride, WAY 267,464 dihydrochloride, WAY 267464 dihydrochloride, WAY-267,464 dihydrochloride, WAY267464 dihydrochloride

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C32H35N7O4 · 2HCl
化学文摘社编号:
1432043-31-6
分子量:
654.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD23135228
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
desiccated

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C32H35N7O4.2ClH/c1-21-13-23(31(42)39-20-25-18-34-36(2)30(25)35-28-5-3-4-6-29(28)39)7-8-24(21)17-33-32(43)38-11-9-37(10-12-38)19-22-14-26(40)16-27(41)15-22;;/h3-8,13-16,18,35,40-41H,9-12,17,19-20H2,1-2H3,(H,33,43);2*1H

SMILES string

O=C(NCC1=CC=C(C=C1C)C(N2CC3=C(NC4=CC=CC=C24)N(N=C3)C)=O)N5CCN(CC5)CC6=CC(O)=CC(O)=C6

InChI key

OTFWXMFLPMUDFP-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

2-8°C

Biochem/physiol Actions

Non-peptide oxytocin receptor (OTR) agonist and vasopressin V1a receptor (V1aR) antagonist.
WAY-267464 is a non-peptide drug with a novel mechanism of action (MOA) to treat psychosis and schizophrenia.
WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist (EC50 = 61-881 nM; Ki = 58-978 nM) that, unlike oxytocin (OT), displays antagonist instead of agonist activity toward vasopressin V1a receptor/V1aR (IC50 = 613 nM; Ki = 27-113 nM). WAY-267464 exhibits OT-like anxiolytic effects in assays measuring both behavioral (33% increase in punished crossing by 10 mg/mL ip or 10 μg/mouse icv in four-plate tests; 75% increased open quadrants stay by 3 μg/mouse icv in elevated zero maze) and autonomic (47% higher stress-induced hyperthermia by 10 μg/mouse icv) parameters of the anxiety response. Similar to the antipsychotic-like effects reported for OT, WAY-267464 also reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine. Unlike OT, WAY-267464 does not affect immobility in mouse tail suspension test.

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000148208
0000148208
0000122072
0000093454
0000040537

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

William T Jorgensen et al.
European journal of medicinal chemistry, 143, 1644-1656 (2017-11-12)
WAY-267,464 (1) and twelve conformationally rigid analogues (3a-f-4a-f) were synthesised, characterised and evaluated in cellular assays with the aim of systematically exploring interactions with the oxytocin receptor (OTR). Each analogue was evaluated in radioligand binding displacement assays at both human
Nisrine Lahoud et al.
Psychoneuroendocrinology, 38(10), 2184-2195 (2013-09-17)
The oxytocinergic system promotes social behavior and reduces anxiety. The significant roles and functional interactions of the medial prefrontal cortex and the amygdala in the regulation of fear provide a unique experimental setting to examine the effects of oxytocin on
Robert H Ring et al.
Neuropharmacology, 58(1), 69-77 (2009-07-21)
The widely reported effects of oxytocin (OT) on CNS function has generated considerable interest in the therapeutic potential for targeting this system for a variety of human psychiatric diseases, including anxiety disorders, autism, schizophrenia, and depression. The utility of synthetic
William T Jorgensen et al.
European journal of medicinal chemistry, 108, 730-740 (2016-01-08)
A previously identified, non-peptidic oxytocin (OT) receptor agonist WAY-267,464 (1) and nine novel derivatives (3, 4a-7a, 4b-7b) were synthesised and evaluated in vitro with the aim of systematically exploring hydrogen bonding interactions and ligand flexibility. All analogues were subjected to competition
C Hicks et al.
British journal of pharmacology, 171(11), 2868-2887 (2014-03-20)
There is current interest in oxytocin (OT) as a possible therapeutic in psychiatric disorders. However, the usefulness of OT may be constrained by peripheral autonomic effects, which may involve an action at both OT and vasopressin V1A receptors. Here, we
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持